Insights into targeting SARS-CoV-2: design, synthesis,in silicostudies and antiviral evaluation of new dimethylxanthine derivatives

Authors:

Abstract
The expanded structure- and ligand-based drug design strategy was utilized to obtain a multitargeting SARS-CoV-2 inhibitor, compound 9a, with an IC50value of 8.86 μM.

This publication has 75 references indexed in Scilit: